Previous close | 17.80 |
Open | 17.80 |
Bid | 13.10 |
Ask | 20.00 |
Strike | 985.00 |
Expiry date | 2024-08-16 |
Day's range | 17.80 - 17.80 |
Contract range | N/A |
Volume | |
Open interest | 19 |
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.